modafinil has been researched along with Breast Cancer in 3 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy of modafinil in patients with metastatic prostate or breast cancer undergoing docetaxel chemotherapy (every 21 days; minimum dose 50 mg/m(2))." | 9.19 | Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. ( Abdi, E; Bonaventura, A; Craft, P; de Souza, P; Hill, A; Hovey, E; Lloyd, A; Marx, G; Michele, A; Parente, P; Rapke, T, 2014) |
| "The authors found that modafinil improved cognitive performance in breast cancer survivors by enhancing some memory and attention skills." | 9.14 | The effect of modafinil on cognitive function in breast cancer survivors. ( Adams, MJ; Fisher, SG; Kohli, S; Mapstone, ME; Morrow, GR; Roscoe, JA; Tra, Y; Wesnes, KA, 2009) |
| "This multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy of modafinil in patients with metastatic prostate or breast cancer undergoing docetaxel chemotherapy (every 21 days; minimum dose 50 mg/m(2))." | 5.19 | Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy. ( Abdi, E; Bonaventura, A; Craft, P; de Souza, P; Hill, A; Hovey, E; Lloyd, A; Marx, G; Michele, A; Parente, P; Rapke, T, 2014) |
| "The authors found that modafinil improved cognitive performance in breast cancer survivors by enhancing some memory and attention skills." | 5.14 | The effect of modafinil on cognitive function in breast cancer survivors. ( Adams, MJ; Fisher, SG; Kohli, S; Mapstone, ME; Morrow, GR; Roscoe, JA; Tra, Y; Wesnes, KA, 2009) |
| "Insomnia was assessed by the Insomnia Severity Index and sleep quality by the Pittsburgh Sleep Quality Inventory." | 2.80 | Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. ( Daniels, NP; Garland, SN; Heckler, CE; Morrow, GR; Peoples, AR; Perlis, ML; Roscoe, JA; Savard, J; Shayne, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hovey, E | 1 |
| de Souza, P | 1 |
| Marx, G | 1 |
| Parente, P | 1 |
| Rapke, T | 1 |
| Hill, A | 1 |
| Bonaventura, A | 1 |
| Michele, A | 1 |
| Craft, P | 1 |
| Abdi, E | 1 |
| Lloyd, A | 1 |
| Roscoe, JA | 2 |
| Garland, SN | 1 |
| Heckler, CE | 1 |
| Perlis, ML | 1 |
| Peoples, AR | 1 |
| Shayne, M | 1 |
| Savard, J | 1 |
| Daniels, NP | 1 |
| Morrow, GR | 2 |
| Kohli, S | 1 |
| Fisher, SG | 1 |
| Tra, Y | 1 |
| Adams, MJ | 1 |
| Mapstone, ME | 1 |
| Wesnes, KA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomised, Double-Blind, Placebo-Controlled Phase III Study of Modafinil to Improve Fatigue and Quality of Life in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer[NCT00917748] | Phase 3 | 84 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Modafinil to Improve Fatiguability (MODIFY): Modafinil vs. Placebo Vanguard RCT[NCT05333250] | Phase 3 | 40 participants (Anticipated) | Interventional | 2024-04-30 | Not yet recruiting | ||
| Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy[NCT01091974] | Phase 2 | 138 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Insomnia Severity Index (ISI) is a commonly used, 7-item psychometrically validated measure used to rate insomnia with 0-7 = absence of insomnia, 8-14 = subthreshold insomnia symptoms, 15-21 = moderate insomnia, and 22-28 = severe insomnia. (NCT01091974)
Timeframe: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 - (CBT-I) + Placebo | -4.93 |
| 2 - CBT-I + Armodafinil | -6.36 |
| 3- Placebo Only | 1.04 |
| 4 - Armodafinil Only | -1.43 |
"The revised Brief Fatigue Inventory (BFI) is a 9-item, patient-report instrument with established reliability and validity. The BFI allows for the rapid assessment of fatigue level in cancer patients and identifies those patients with severe fatigue. Three items ask patients to rate their fatigue now, and fatigue at its worst and usual for the last 24 hours. The 11-point scales are bounded by 0 = no fatigue and 10 = fatigue as bad as you can imagine. Using the same type of scales, the remaining questions ask patients to rate how their fatigue interferes with several functional domains, including general activity, walking, mood, work, and relations with others. These scales are bounded by 0 = does not interfere and 10 = interferes completely. A global fatigue score (ranging from 0-10) can be obtained by averaging all the items on the BFI." (NCT01091974)
Timeframe: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre).
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 - (CBT-I) + Placebo | 2.041 |
| 2 - CBT-I + Armodafinil | 1.209 |
| 3- Placebo Only | 2.971 |
| 4 - Armodafinil Only | 3.167 |
3 trials available for modafinil and Breast Cancer
| Article | Year |
|---|---|
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Doceta | 2014 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Doceta | 2014 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Doceta | 2014 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Doceta | 2014 |
Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment.
Topics: Benzhydryl Compounds; Breast Neoplasms; Cognitive Behavioral Therapy; Combined Modality Therapy; Fem | 2015 |
The effect of modafinil on cognitive function in breast cancer survivors.
Topics: Adult; Aged; Aged, 80 and over; Attention; Benzhydryl Compounds; Breast Neoplasms; Cognition; Fatigu | 2009 |